

Angiotensin receptor blockers and β blockers in Marfan syndrome: an individual patient data meta-analysis of randomised trials



Alex Pitcher, Enti Spata, Jonathan Emberson, Kelly Davies, Heather Halls, Lisa Holland, Kate Wilson, Christina Reith, Anne H Child, Tim Clayton, Matthew Dodd, Marcus Flather, Xu Yu Jin, George Sandor, Maarten Groenink, Barbara Mulder, Julie De Backer, Arturo Evangelista, Alberto Forteza, Gisela Teixido-Turà, Catherine Boileau, Guillaume Jondeau, Olivier Milleron, Ronald V Lacro, Lynn A Sleeper, Hsin-Hui Chiu, Mei-Hwan Wu, Stefan Neubauer, Hugh Watkins, Hal Dietz, Colin Baigent, on behalf of The Marfan Treatment Trialists' Collaboration

Summary

Background Angiotensin receptor blockers (ARBs) and β blockers are widely used in the treatment of Marfan syndrome to try to reduce the rate of progressive aortic root enlargement characteristic of this condition, but their separate and joint effects are uncertain. We aimed to determine these effects in a collaborative individual patient data meta-analysis of randomised trials of these treatments.

Methods In this meta-analysis, we identified relevant trials of patients with Marfan syndrome by systematically searching MEDLINE, Embase, and CENTRAL from database inception to Nov 2, 2021. Trials were eligible if they involved a randomised comparison of an ARB versus control or an ARB versus β blocker. We used individual patient data from patients with no prior aortic surgery to estimate the effects of: ARB versus control (placebo or open control); ARB versus β blocker; and indirectly, β blocker versus control. The primary endpoint was the annual rate of change of body surface area-adjusted aortic root dimension Z score, measured at the sinuses of Valsalva.

Findings We identified ten potentially eligible trials including 1836 patients from our search, from which seven trials and 1442 patients were eligible for inclusion in our main analyses. Four trials involving 676 eligible participants compared ARB with control. During a median follow-up of 3 years, allocation to ARB approximately halved the annual rate of change in the aortic root Z score (mean annual increase 0.07 [SE 0.02] ARB vs 0.13 [SE 0.02] control; absolute difference -0.07 [95% CI -0.12 to -0.01]; $p=0.012$). Prespecified secondary subgroup analyses showed that the effects of ARB were particularly large in those with pathogenic variants in fibrillin-1, compared with those without such variants (heterogeneity $p=0.0050$), and there was no evidence to suggest that the effect of ARB varied with β -blocker use (heterogeneity $p=0.54$). Three trials involving 766 eligible participants compared ARBs with β blockers. During a median follow-up of 3 years, the annual change in the aortic root Z score was similar in the two groups (annual increase -0.08 [SE 0.03] in ARB groups vs -0.11 [SE 0.02] in β -blocker groups; absolute difference 0.03 [95% CI -0.05 to 0.10]; $p=0.48$). Thus, indirectly, the difference in the annual change in the aortic root Z score between β blockers and control was -0.09 (95% CI -0.18 to 0.00; $p=0.042$).

Interpretation In people with Marfan syndrome and no previous aortic surgery, ARBs reduced the rate of increase of the aortic root Z score by about one half, including among those taking a β blocker. The effects of β blockers were similar to those of ARBs. Assuming additivity, combination therapy with both ARBs and β blockers from the time of diagnosis would provide even greater reductions in the rate of aortic enlargement than either treatment alone, which, if maintained over a number of years, would be expected to lead to a delay in the need for aortic surgery.

Funding Marfan Foundation, the Oxford British Heart Foundation Centre for Research Excellence, and the UK Medical Research Council.

Copyright © 2022 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.

Introduction

Marfan syndrome is a genetic disorder, usually caused by pathogenic variants in the fibrillin-1 (*FBN1*) gene that causes progressive enlargement of the aortic root. If unchecked, aortic enlargement in Marfan syndrome can lead to life-threatening aortic dissection, sometimes in early adulthood.¹⁻⁷ Initial treatment is aimed at slowing aortic root growth, and β blockers are widely used for this

purpose, but their use is based mainly on the results of observational studies^{8,9} and one small randomised trial.¹⁰

The discovery that transforming growth factor β (TGF β) dysregulation is implicated in the pathogenesis of some aortic aneurysms led to the hypothesis that angiotensin receptor blockade (which attenuates TGF β activity) might slow aortic root growth in Marfan syndrome.^{11,12} Favourable results in animal models¹¹ and in small observational

Published Online
August 29, 2022
[https://doi.org/10.1016/S0140-6736\(22\)01534-3](https://doi.org/10.1016/S0140-6736(22)01534-3)

See Online/Comment
[https://doi.org/10.1016/S0140-6736\(22\)01642-7](https://doi.org/10.1016/S0140-6736(22)01642-7)

The Heart Centre, John Radcliffe Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, UK (A Pitcher DPhil, XY Jin FRCP); MRC Population Health Research Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK (E Spata MSc, Prof J Emberson PhD, K Davies BSc, H Halls BSc, L Holland PhD, Prof C Baigent FMedSci); Clinical Trial Service Unit and Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK (E Spata, Prof J Emberson, K Davies, H Halls, L Holland, K Wilson DPhil, C Reith PhD, Prof C Baigent); Royal Brompton and Harefield Hospitals Unit, Guy's and St Thomas' NHS Trust and Department of Surgery and Oncology, Imperial College London, London, UK (A H Child FRCP); Clinical Trials Unit, Department of Medical Statistics, London School of Hygiene & Tropical Medicine, London, UK (Prof T Clayton MSc, M Dodd MSc); Faculty of Medicine and Health Sciences, University of East Anglia, Norwich, UK (Prof M Flather MBBS); Children's Heart Centre, British Columbia's Children's Hospital, Vancouver, BC, Canada (Prof G Sandor MBChB); Department of Paediatrics, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada (Prof G Sandor);

Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands (M Groenink PhD); Center for Medical Genetics and Department of Cardiology, Ghent University Hospital, Ghent, Belgium (Prof J De Backer PhD); Servei de Cardiologia, Hospital Universitari Vall d'Hebron, Barcelona, Spain (Prof A Evangelista PhD); Hospital Puerta de Hierro, Majadahonda, Spain (A Forteza PhD); Department of Cardiology, Hospital Universitari Vall d'Hebron, CIBER-CV, Vall d'Hebron Institut de Recerca, Universitat Autònoma de Barcelona, Barcelona, Spain (G Teixido-Turà PhD); Université Paris Cité and Université Sorbonne Paris Nord, Inserm U1148, LVT5, F-75018 Paris, France (Prof C Boileau PhD, Prof G Jondeau PhD, O Milleron MD); Service de Cardiologie (Prof C Boileau, Prof G Jondeau, O Milleron); CRM Syndrome de Marfan et apparentés (Prof C Boileau, Prof G Jondeau, O Milleron), AP-HP Hôpital Bichat-Claude Bernard, F-75018, Paris, France; Department of Cardiology, Boston Children's Hospital, Boston, MA, USA (R V Lacro MD, L A Sleeper ScD); Department of Pediatrics, Harvard Medical School, Boston, MA, USA (R V Lacro, L A Sleeper); Department of Pediatrics, Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, New Taipei City, Taiwan (H-H Chiu PhD); Department of Pediatrics and Adult Congenital Heart Center, National Taiwan University Hospital, Taipei, Taiwan (Prof M-H Wu PhD); Oxford Centre for Clinical Magnetic Resonance Research, Division of Cardiovascular Medicine (Prof S Neubauer MD), Radcliffe Department of Medicine, University of Oxford, Oxford, UK (A Pitcher, Prof H Watkins DPhil); Howard Hughes Medical Institute and Department of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA (Prof H Dietz MD); European Reference Network for Rare

Research in context

Evidence before this study

We searched Embase, MEDLINE, and CENTRAL from inception until Nov 2, 2021, for randomised trials that assessed the effects of angiotensin receptor blocker (ARB) versus control or ARB versus β blockers in patients with Marfan syndrome. Cochrane search filters were used in Embase and Medline to identify randomised trials, and the terms "Marfan" or "Marfan syndrome" were used in all three databases (appendix p 2). The searches were not restricted to English language publications. We identified a number of randomised trials of ARB versus placebo (or open control) in which the aim was to estimate the effects of treatment with ARBs on aortic root size in patients with Marfan syndrome. Several meta-analyses of published data from these trials were also identified, but none were able to define the effects of ARBs in different circumstances, including according to age, sex, or blood pressure, but also according to whether or not a β blocker was part of existing treatment, and whether or not a diagnosis of Marfan syndrome had been confirmed by genotyping. There were no large, randomised trials assessing the efficacy of a β blocker for Marfan syndrome, despite the fact that such treatment is used widely for this condition.

studies in humans^{12–14} led to several randomised trials in patients with Marfan syndrome, the first of which was published in 2013.^{15–24} Combining these trials could increase the precision in estimates of treatment effect and increase the power of subgroup analyses. In 2012, we established a collaborative group (the Marfan Treatment Trialists' [MTT] Collaboration) to do a meta-analysis of individual patient data from all relevant Marfan syndrome trials. A protocol was subsequently agreed for the rationale, design, and conduct of the meta-analysis.²⁵

Since 2012, most of the participating trial groups in the MTT Collaboration have reported their results,^{15–18,20–24} and several meta-analyses of published data have been reported.^{26–28} Two of these meta-analyses^{26,28} did not include the recent UK-based AIMS trial,²³ but one that did include this trial²⁷ concluded that angiotensin receptor blockers (ARBs) are effective when used alone or when added to a β blocker. Since this meta-analysis included only published data, it was subject to biases that might arise from selective reporting of findings in publications, and it was not able to harmonise definitions of aortic root size for all trials or explore treatment effects in detail (eg, among particular prognostic subgroups such as those with a confirmed *FBNI* pathogenic variant). The present report describes a meta-analysis in which the availability of individual patient data removes these limitations, allowing a more complete assessment of ARBs in Marfan syndrome. By prespecifying the use of indirect comparisons of trials of an ARB versus control and of an ARB versus β blocker, our report also provides

Added value of this study

This meta-analysis of individual patient data from randomised trials, which followed a protocol that was agreed and published before any analyses, showed that ARBs reduced the rate of aortic root enlargement by about one half, and that this effect was generalisable to different types of patients. In particular, ARBs were effective even among those already taking a β blocker. The estimated effect of ARBs was significantly greater among those with a pathogenic variant in fibrillin-1, than those without such a fibrillin-1 variant, providing biological support for the effect. β blockers were estimated to have a similar beneficial effect as ARBs.

Implications of all the available evidence

If tolerated, the combination of a β blocker and an ARB could reduce the rate of enlargement of the aortic root by at least one half, and potentially by much more than this. Although this meta-analysis of trials did not have sufficient power to assess effects on the need for surgery (and it is unlikely that any randomised study will ever be done to study this question directly), as elective surgery is almost always driven by aortic root size and rate of expansion, our results suggest that long-term combination therapy could eventually reduce such outcomes.

an assessment of the effects of β -blocker therapy given alone and the effects of combined ARB and β -blocker therapy.

Methods

Study design and outcomes

In this meta-analysis, we identified relevant trials by systematically searching MEDLINE, Embase, and CENTRAL from database inception to Nov 2, 2021. Trials were eligible if they involved a randomised comparison of an ARB versus control or an ARB versus β blocker in patients with Marfan syndrome and if patient-level data were available. A description of the search terms is in the appendix (p 2). The review of search results was done independently by two authors (including HH, KD, KW, and LH) and adjudicated by either AP or CBa. Relevant trials were also sought through enquiry with authors of collaborating trials.²⁵ Each trial was reviewed for eligibility by reviewing its protocol and methods, and clarification was sought as necessary by discussion with the authors of the relevant trial. Bias was accounted for by including only properly randomised, unconfounded trials in the main analyses. Sources of variability within and between studies was controlled by a harmonised definition of patients to be included in the analyses, and explored by prespecified subgroup analyses. The protocol for our study has been published.²⁵ The primary aims of this meta-analysis were to estimate the effects of ARB and β blockers on the change in aortic root size in patients with Marfan syndrome and no previous aortic root

surgery. Thus, patients with previous aortic root surgery in the identified trials were excluded from analyses. The primary comparisons involved only the unconfounded trials (ie, trials that had no protocol-mandated differences between randomised groups other than those created by the randomised allocations), but a sensitivity analysis included one trial²² in which there were different dosing strategies for β blockers in the ARB and control groups of the study. The prespecified primary outcome was the annual rate of change of body surface area (BSA)-adjusted aortic root dimension Z score, measured at the sinuses of Valsalva. The secondary outcome was the annual rate of change of the absolute aortic root dimension measured at the sinuses of Valsalva. Other secondary aims were to assess those effects across different subgroups defined on the basis of patients' characteristics at baseline; to assess effects on cardiovascular outcomes, including aortic dissection, aortic root surgery and death, as well as the composite of these three outcomes; and to assess effects on a range of other outcomes and measures that were sufficiently complete to permit meaningful analyses (appendix p 4).

Data analysis

We requested individual participant data on relevant characteristics including age, sex, previous aortic surgery, family history of Marfan syndrome, pathogenic variants in relevant genes, ectopia lentis, β -blocker usage, physical measurements, and blood pressure. We also collected data on aortic measurements, surgery, dissection, and death during the trial. The data analysis methods used in our study have been published elsewhere.²⁵ Z scores were calculated using the method used by each trial (as reported in their main analysis) except in cases in which values were provided directly by the trialist. Secondary analyses using the methods of Campens and colleagues²⁹ and Pettersen and colleagues³⁰ were done to explore the effect of using an alternative method to estimate aortic root Z score. A two-stage meta-analysis approach was used. For each patient, a linear slope of the annual rate of change (from baseline) of the BSA-adjusted Z score was calculated. The difference in mean slopes between treatment groups (and its SE) was then calculated for each trial and standard inverse-variance-weighted methods were used to estimate the overall inverse-variance-weighted average difference in slopes across all trials. A random effects meta-analysis, which assumes that the underlying set of trials are representative of an underlying population of possible trial designs, was also done as a sensitivity analysis. Patients with missing data on rate of change in aortic root Z score were excluded. To allow for multiple subdivisions of the data, only summary effect estimates are presented with 95% CIs; all other effect estimates (such as results from individual trials or in particular patient subgroups) are presented with 99% CIs.

An indirect assessment of the effect of β blockers compared with controls was calculated using indirect comparisons of trial results³¹ as follows: if d_1 (with variance v_1) is the difference in mean annual rate of change in aortic root Z scores estimated from the three trials that compared ARB with β blockers and d_2 (with variance v_2) is the difference in mean annual rate of change in aortic root Z scores estimated from the four trials that compared ARB with controls, then an indirect estimate of the effect of β blockers is provided by $d_2 - d_1$ (which has variance equal to $v_1 + v_2$). This indirect analysis assumes that the effects of ARBs and β blockers are additive (that is, the effect of an ARB is the same if a β blocker is given or not and the effect of a β blocker is the same irrespective of whether an ARB is given or not).

For the primary comparisons, a two-sided p value less than 0.05 was considered significant. Analyses were done using SAS version 9.4 and R version 3.5.0. The MTT database is a research database, and did not involve accessing or otherwise processing patient-identifiable information, and hence did not require ethical approval.

Role of the funding source

The funders of the study had no role in study design, data collection, data analysis, data interpretation, writing of the report, or the decision to submit.

Results

We identified ten trials with a total of 1836 patients as being potentially eligible for the study (table 1; appendix p 7).¹⁵⁻²⁴ Three trials, with a total of 324 patients, were not included in the primary analyses: one trial (262 patients) was published as an abstract only and was unable to contribute data;³² one trial (34 patients) was published but unable to contribute data;¹⁶ and one trial (28 patients) contributed data but was found to be confounded owing to protocol-mandated adjustment in β -blocker doses in the control group²² (this trial contributed only to a sensitivity analysis). Of the seven remaining trials, 70 (4.6%) of the 1512 randomised patients were excluded because they had had previous aortic root surgery. The main analyses therefore include individual data from 1442 participants in seven trials.^{15,17,18,20-24}

Data for the primary analysis were available from four trials of ARB versus control, including 676 patients (excluding 70 patients with previous aortic root surgery at enrolment; 353 assigned to ARB and 323 to control).^{15,18,20,23} The mean age of participants in these trials was 29 years (SD 14), 367 (54%) were female and 507 (75%) were receiving β blockers at baseline (all trials allowed patients to remain on their β blockers). Overall, 526 (83%) of 630 genotyped individuals had an *FBN1* pathogenic variant (table 2). The mean Z score at the sinuses of Valsalva at baseline was 3.76 (SD 2.14) in patients allocated to ARB and 3.64 (SD 1.94) in patients allocated to control. The mean annual change of the Z score during follow-up was 0.07 (SE 0.02) in the ARB group and

Multisystemic Vascular Disease (VASCERN), HTAD Rare Disease Working Group, Amsterdam, The Netherlands (M Groenink, Prof B Mulder); European Reference Network for Rare Multisystemic Vascular Disease (VASCERN), HTAD Rare Disease Working Group, Ghent, Belgium (Prof J De Backer); European Reference Network for Rare Multisystemic Vascular Disease (VASCERN), HTAD Rare Disease Working Group, Barcelona, Spain (Prof A Evangelista, G Teixeira-Turà); European Reference Network for Rare Multisystemic Vascular Disease (VASCERN), HTAD Rare Disease Working Group, Paris, France (Prof C Boileau, Prof G Jondeau, O Milleron)

Correspondence to: Prof Colin Baigent, MRC Population Health Research Unit, Clinical Trial Service Unit and Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, Oxford OX3 7LF, UK colin.baigent@ndph.ox.ac.uk

See Online for appendix

Treatment comparison (daily doses)		Number of randomly assigned patients	Median age, years	Median follow-up, months	Measures collected, months	Data provided to MTT secretariat	Main outcome measures						
							Body surface area			Aortic dimension at the sinuses of Valsalva			
							Method	Baseline, mean (SD)	Methods	Baseline, mean (SD)	Method	Baseline, mean (SD)	
ARB vs control (placebo or open control)													
Marfan Sartan ¹⁸	Losartan (50–100 mg) vs placebo	299	26	42	0, 6, 12, 18, 24, 30, 36, 42, 48, 54, 60	Yes	*	1.83 (0.27)	Echo, end diastole, and leading edge to leading edge	38.8 (5.8)	Roman and colleagues ³³	3.60 (2.15)	
COMPARE ²⁰	Losartan (50–100 mg) vs open control	233	35	36	0, 36	Yes		2.02 (0.24)	MRI, end diastole, and inner edge to outer edge	44.3 (5.2)	†	4.42 (1.75)	
AIMS ³	Irbesartan (150–300 mg) vs placebo	192	18	46	0, 12, 24, 36, 48, 60	Yes		1.71 (0.40)	Echo, peak systole, and inner edge to inner edge	34.4 (5.6)	Devereux and colleagues ³⁶	3.24 (2.04)	
Ghent Marfan ¹⁵	Losartan (25–100 mg) vs placebo	22	36	36	0, 6, 12, 24, 36	Yes		1.98 (0.24)	Echo and leading edge to leading edge	41.2 (3.5)	†	3.55 (1.04)	
Taiwanese trial ²²	Losartan plus β blocker vs β blocker [‡]	28	13	35	0, 6, 12, 18, 24, 30, 35	Yes (but only included in sensitivity analyses)		1.39 (0.38)	Echo and inner edge to inner edge	32.9 (6.1)	†	2.07 (1.89)	
Italian trial ¹⁹	Losartan (100 mg adults or ≤ 1.4 mg/kg children) plus nebivolol (10 mg adults or ≤ 0.16 mg/kg children) vs nebivolol (10 mg adults or ≤ 0.16 mg/kg children)	160§	Unknown	48	0, 12, 24, 36, 48	No (trial yet to publish its full results)		Unknown	
ARB vs β blocker													
PHN ²⁴	Losartan (0.4–1.4 mg/kg) vs atenolol (0.5–4.0 mg/kg)	608	11	36	0, 6, 12, 24, 36	Yes		1.28 (0.48)	Echo, systole, and inner edge to inner edge	33.6 (7.1)	Sluysmans and Colan ³⁷	4.32 (1.35)	
LOAT ²¹	Losartan (12.5–100 mg) vs atenolol (12.5–100 mg)	140	26	36	0, 36	Yes		1.75 (0.36)	MRI and end diastolic frame	36.1 (6.2)	Devereux and colleagues ³⁸	3.17 (2.21)	
Canadian trial ¹⁷	Losartan (25 mg) vs atenolol (25–50 mg)	18	17	12	0, 3, 6, 9, 12	Yes		1.77 (0.22)	Echo and trailing edge to leading edge	39.0 (5.8)	†	3.55 (1.93)	
Italian trial ¹⁹	Losartan (100 mg adults or ≤ 1.4 mg/kg children) vs nebivolol (10 mg adults or ≤ 0.16 mg/kg children)	155§	Unknown	48	0, 12, 24, 36, 48	No (trial yet to publish its full results)		Unknown	
Boston, USA trial ¹⁶	Losartan (100 mg) vs atenolol (50 mg)	34	35	6	0, 6	No (trialist unable to provide data)		Unknown	

For each trial, the imaging method used to estimate aortic root dimension was the method used in that trial's primary analysis. ARB=angiotensin receptor blocker; MTT=Marfan Treatment Trialists. *Data not provided by the trialist so estimated using the DuBois and Du Bois³⁵ method. †Data not provided by the trialist so estimated using the Devereux and colleagues³⁶ method. ‡Adults were randomly assigned to losartan (25–100 mg per day) plus β blocker (at a low maintenance dose [50 mg atenolol once daily or 20 mg propranolol twice daily]) vs β blocker (atenolol or propranolol, maximum 150 mg per day), and children were randomly assigned to losartan (0.7 mg/kg per day, to a maximum of 50 mg per day) plus β blocker (low maintenance dose, 1 mg/kg per day atenolol or propranolol) vs β blocker (atenolol or propranolol) vs β blocker (atenolol or propranolol, maximum 2 mg/kg per day). §Number reported in trialists' abstract was number analysed (the total number of patients randomly assigned across all three groups of the Italian trial was 262).

Table 1. Characteristics of ten trials of angiotensin receptor blockers in patients with Marfan syndrome

0.13 (SE 0.02) in the control group, corresponding to a mean difference of -0.07 (95% CI -0.12 to -0.01 ; $p=0.012$; figure 1), which represents an approximate halving in the annual rate of change in the aortic root Z score in the ARB group compared with the control group.

Although there was no evidence of heterogeneity between the overall results of the four contributing trials (heterogeneity $p=0.11$; figure 1), within these trials, there was significant heterogeneity of treatment effects with an ARB between the 490 participants with a documented pathogenic variant in *FBN1*, compared with the 95 participants who did not have a pathogenic variant in *FBN1* (figure 2; appendix p 8; heterogeneity $p=0.0050$). There was no significant heterogeneity of the effects of an ARB in any of the other prespecified subgroups. In particular, the mean annual change in aortic root Z score was similar irrespective of whether or not patients were taking a β blocker at baseline (heterogeneity $p=0.54$).

Secondary analyses were done to assess the sensitivity of the findings to different methods of aortic root size measurement. For the secondary outcome of absolute aortic dimension, the mean annual change was 0.38 mm (SE 0.04) in patients allocated ARB and 0.52 mm (SE 0.04) in patients allocated control, resulting in a mean difference of -0.14 mm (95% CI -0.26 to -0.02 ; $p=0.025$; appendix p 9). Findings were similar when the analysis included one confounded trial²² in which there were different dosing strategies for β blockers in the ARB and control groups during the study (mean difference -0.08 [95% CI -0.13 to -0.03]; $p=0.0009$; appendix p 10), and were also similar when the Z scores were calculated using the method described by Campens and colleagues²⁹ (mean difference -0.04 [95% CI -0.07 to -0.01]; $p=0.0071$; appendix p 11) or by Pettersen and colleagues³⁰ (mean difference -0.04 [95% CI -0.07 to -0.01]; $p=0.017$; appendix p 12).

Individual participant data were available from three trials of ARB versus β blockers, including 766 patients (384 assigned to ARB and 382 to β blocker).^{17,21,24} The mean age of participants was 14 years (SD 10); 336 (44%) of 766 were female, and 280 (86%) of 327 genotyped individuals had a pathogenic variant in *FBN1* (table 2). The baseline mean Z score was 4.18 (SD 1.71) in patients allocated to ARB and 4.03 (SD 1.50) in patients allocated to β blocker. The mean annual change of the Z score during follow-up was -0.08 (SE 0.03) in the ARB group and -0.11 (SE 0.02) in the β -blocker group, and the mean difference in the change in Z scores between ARB groups and β -blocker groups was not significant (0.03 [95% CI -0.05 to 0.10]; $p=0.48$; figure 1). There were no significant differences in aortic Z score when using other methods^{29,30} (appendix pp 11–12). Similarly, there were no significant differences between the two groups in other measures of change in aortic dimensions, including absolute aortic dimension

	ARB vs control		ARB vs β blocker	
	ARB (n=353)	Control (n=323)	ARB (n=384)	β blocker (n=382)
Median follow-up, years	3.0 (2.9–4.0)	3.0 (3.0–4.0)	3.0 (3.0–3.0)	3.0 (3.0–3.0)
Mean age, years	28.8 (14.7)	28.3 (13.8)	13.9 (9.9)	13.9 (9.7)
Age, years				
<16	75 (21%)	67 (21%)	258 (67%)	254 (66%)
≥ 16 to <25	80 (23%)	78 (24%)	82 (21%)	88 (23%)
≥ 25 to <40	114 (32%)	119 (37%)	37 (10%)	31 (8%)
≥ 40	84 (24%)	59 (18%)	7 (2%)	9 (2%)
Gender				
Male	164 (46%)	145 (45%)	218 (57%)	212 (55%)
Female	189 (54%)	178 (55%)	166 (43%)	170 (45%)
Family history of Marfan syndrome				
Yes	100 (28%)	82 (25%)	187 (49%)	188 (49%)
No	164 (46%)	158 (49%)	111 (29%)	116 (30%)
Unknown	89 (25%)	83 (26%)	86 (22%)	78 (20%)
Family history of aortic dissection				
Yes	6 (2%)	1 (<1%)	55 (14%)	58 (15%)
No	4 (1%)	4 (1%)	258 (67%)	254 (66%)
Unknown	343 (97%)	318 (98%)	71 (18%)	70 (18%)
Presence of <i>FBN1</i>				
Yes	270 (76%)	256 (79%)	135 (35%)	145 (38%)
No	59 (17%)	45 (14%)	27 (7%)	20 (5%)
Unknown	24 (7%)	22 (7%)	222 (58%)	217 (57%)
Ectopia lentis				
Yes	84 (24%)	67 (21%)	129 (34%)	133 (35%)
No	116 (33%)	108 (33%)	150 (39%)	134 (35%)
Unknown	153 (43%)	148 (46%)	105 (27%)	115 (30%)
Current β -blocker use	265 (75%)	242 (75%)	0	0
Aorta at the sinuses of Valsalva				
Mean dimension, mm	39.0 (6.8)	38.9 (6.5)	34.2 (7.0)	34.2 (7.1)
Mean Z score	3.76 (2.14)	3.64 (1.94)	4.18 (1.71)	4.03 (1.50)
Other baseline measures				
Mean weight, kg	67.6 (19.7)	69.6 (21.3)	45.0 (23.7)	46.5 (23.7)
Mean height, cm	178 (15)	179 (15)	155 (31)	156 (32)
Mean systolic blood pressure, mm Hg	117 (16)	117 (15)	102 (16)	102 (16)
Mean diastolic blood pressure, mm Hg	70 (11)	70 (10)	62 (11)	62 (11)
Mean heart rate, beats per min	64 (14)	65 (14)	78 (18)	77 (17)
Mean body surface area, m ²	1.83 (0.32)	1.86 (0.33)	1.36 (0.49)	1.40 (0.50)
Mean BMI, kg/m ²	20.9 (4.6)	21.3 (5.3)	17.3 (4.0)	17.5 (4.0)

Data are n (%), median (IQR), or mean (SD). 70 patients with previous aortic root surgery at enrolment were excluded: two in the ARB group and five in the placebo group from Ghent Marfan and 27 in the ARB group and 36 in the control group from COMPARE. ARB=angiotensin receptor blocker. *FBN1*=fibrillin-1.

Table 2: Baseline characteristics by randomised allocation

(appendix p 9). There was some evidence of heterogeneity in the Z score difference between ARB and β blockers depending on family history of aortic dissection (favouring ARB in the 110 patients with such a family history, heterogeneity $p=0.010$), but otherwise no evidence of heterogeneity in any of the other prespecified subgroups (figure 3).




Figure 1: Annual rate of change of body surface area-adjusted aortic root dimension Z score at the sinuses of Valsalva
Indirect effect of β blocker vs control is -0.09 (95% CI -0.18 to 0.00); p value=0.042 (β blocker minus control). ARB=angiotensin receptor blocker.

In the trials of ARB versus control, there was no significant difference in the proportion of patients who had the composite outcome of aortic dissection, aortic root surgery, or death during study follow-up (30 [8%] of 353 ARB vs 27 [8%] of 323 control, $p=0.86$). Nor was there any evidence of difference in this composite outcome in the trials of ARB versus β blockers (21 [5%] of 384 ARB vs 14 [4%] of 382 β blockers, $p=0.23$; appendix p 3).

Combining the results of the four trials of ARB versus control with the three trials of ARB versus β blockers allowed us to indirectly assess β blockers versus control. With such an analysis, the difference in mean absolute annual change in the aortic root Z score between β blocker and control was -0.09 (95% CI -0.18 to 0.00; $p=0.042$; ie, similar to the direct estimate when comparing ARB with control). Since the trials of ARB versus control and ARB versus β blockers included patients within different age ranges, in a post-hoc exploratory analysis we examined the indirect comparison of β blockers versus control separately in patients younger than 16 years and patients aged 16 years or older. We found no evidence that the effect of a β blocker differed in those younger than 16 years compared with those aged 16 years and older (heterogeneity $p=0.09$).

We also prespecified a range of other secondary analyses in our published protocol.²⁵ These included assessments of aortic dimension at locations other than the sinuses of Valsalva, assessments using different imaging methods, and analyses of haemodynamic variables (eg, blood pressure) and other physical measurements. The numbers of patients available for such analyses varied, depending on what was included in each trial's case report forms, and the results are summarised in the appendix (p 4). None of these results are qualitatively

inconsistent with the main findings. Additionally, we prespecified exploratory analyses using a random effects model: the absolute differences for each of these were similar to those derived from our prespecified method of analysis (a so called fixed effect analysis), but with wider CIs (as would be expected; appendix p 6). Finally, we prespecified that for baseline groups defined by age, systolic blood pressure, diastolic blood pressure, and BSA-adjusted Z score we would do additional interaction tests in which these factors were considered as continuous rather than categorical variables. For all eight interaction tests (four in each of the two groups of trials) there was no good evidence that the effect on aortic root dimension Z score varied significantly depending on the baseline characteristic (the smallest of these interaction p values was 0.05, which is not significant given the multiple tests that were done).

Discussion

Marfan syndrome affects about one in 5000 people, which corresponds to a global total of 1.6 million people.³⁸ Marfan syndrome causes a dramatically increased risk of aortic complications, mainly aortic dissection, commonly resulting in premature death or disability: a 2018 study reported 11 fatal aortic complications among 412 patients with Marfan syndrome, compared to only six such complications among 41500 age-matched and sex-matched controls over a comparable period (hazard ratio 194.6 [95% CI 67.4–561.7]).⁷ Prophylactic surgery to replace the aortic root is recommended in cases in which a large or rapidly expanding aneurysm presents an imminent risk of aortic dissection, but such surgery is itself associated with morbidity, occasional mortality, and is not available in all health-care systems. Effective medical therapy that is well-tolerated by both children




Figure 2: Annual rate of change of BSA-adjusted aortic root dimension Z score at the sinuses of Valsalva, by subgroups (ARB vs control)
ARB=angiotensin receptor blocker. BSA=body surface area.

and adults could delay or prevent the need for surgery. This meta-analysis shows that among patients with Marfan syndrome who had had no previous aortic surgery, an ARB reduces the rate of increase of the aortic root Z score by around one half and that this effect seems to be in addition to any effects of β blockers (which are discussed later). The robustness of our findings on the effects of an ARB is reinforced by several observations that, since they depended on the availability of individual participant data, went beyond the results of previous meta-analyses of tabular data.²⁶⁻²⁸ The first of these observations is that, although in general there was little evidence of heterogeneity of the effect of ARBs among the prespecified subgroups, ARBs had a significantly greater effect on aortic root dimension Z score among

patients with a known pathogenic variant in the *FBN1* gene. Given that *FBN1* variant status is a marker of the certainty of a diagnosis of Marfan syndrome, this finding is what might be expected if an ARB is effective at slowing root expansion in this condition. The second observation was that all of the prespecified methods for estimating change in root size yielded significant results, so that our findings were not dependent on the performance of a particular method; this, again, is as might be expected if an ARB is effective. Our analyses are most informative about the effects of an ARB, because these analyses involved meta-analyses of trials making direct comparisons of an ARB versus control. Our results are less definitive for β blockers than ARBs, because the β -blocker analyses




Figure 3: Annual rate of change of BSA-adjusted aortic root dimension Z score at the sinuses of Valsalva, by subgroups (ARB vs β blocker)
ARB=angiotensin receptor blocker. BSA=body surface area.

depended on indirect comparisons of two groups of trials (four comparing an ARB vs control and three comparing an ARB vs a β blocker). Our indirect estimate of the effect of β blockers is consistent with the results of one small trial that directly compared a β blocker with no treatment.¹⁰ However, our estimates rely on the assumption that the effects of ARBs and β blockers are independent of each other (ie, that the effects of each drug on change in aortic Z score are additive). Our observation of no significant heterogeneity of the effect of ARBs depending on concomitant use of β blockers suggests this assumption is a reasonable one, but does not prove the assumption to be correct. Since the trials of an ARB versus control and of an ARB versus a β blocker differed substantially in

average age at entry (13.9 years for ARB vs β blockers and 28.5 years for ARB vs control), we assessed the separate effects of a β blocker in those younger than 16 years and those aged 16 years and older in stratified analyses. Although we found no evidence that effects of β blockers varied significantly depending on age, there was little power to detect any true heterogeneity that might have been present.

The clinical significance of our results is informed by sample size calculations done by the Pediatric Heart Network investigators²⁴ who assumed that, in an adult Marfan syndrome population with a mean age of 20 years and Z score of 4.3, the threshold for aortic surgery would be reached in about 15 years (when the Z score is 7.3 and the aortic root diameter is 5.04 cm).

Reducing this annual rate of change from 0.20 to 0.12 (ie, annual reduction of 0.08) would therefore increase the expected time to surgery by about 10 years (since, at an annual increase in Z score of 0.12 rather than 0.20, it would take 25 rather than 15 years for the Z score to increase from 4.3 to 7.3). Such an annual reduction is consistent with the absolute changes in Z score in our analyses (−0.07 for an ARB and −0.09 for a β blocker).

A limitation of our analysis is that, despite making every effort to obtain all available trial datasets, not all were available for individual data analysis: one published trial¹⁶ did not contribute data but was very small (34 participants followed up for only 6 months) and its conclusions were consistent with the results of the meta-analysis, so it would not have influenced our conclusions. Another trial, of moderate size ($n=262$, follow-up 48 months), was not available from the investigators.³² The main findings of this second trial from which data were unavailable have, however, been reported in abstract form and showed that the combination of an ARB (losartan) and a β blocker (nebivolol) reduced progression as compared with either treatment alone ($p=0.009$),³² which is consistent with the main findings of the meta-analysis. Of the trials included in our meta-analysis, one used irbesartan²³ and losartan was used in the others, hence the amount of data available for irbesartan was scarce compared with that for losartan. No trials randomly allocated participants to prespecified ARB dosing strategies or to different agents. Consequently, it was not possible to explore whether any particular ARB selection or dosing strategy was superior to any other (and similar limitations apply to β blockers). The generalisability of our findings to older adults with Marfan syndrome is somewhat uncertain, as only 11% of the randomly assigned patients were aged 40 years or older and only 6% were aged 50 years or older. Finally, even in this meta-analysis of all eligible and available trials, the number of patients who had major clinical outcomes was too small to provide sufficient statistical power to detect benefit on such outcomes over the relatively short duration of the trials.

In summary, in these trials of patients with Marfan syndrome, ARBs reduced the rate of enlargement of the aortic root by about one half, including among those already taking a β blocker. The effect was particularly large among patients with a pathogenic *FBN1* variant, strengthening the main finding. The effects of β blockers were similar in magnitude to those of ARBs. Moreover, for ARB versus control, there was no evidence that the effect size depended on use of β blockers. Our findings therefore suggest that, if tolerated, the combination of a β blocker and ARB would reduce the rate of enlargement of the aortic root by at least one half, and potentially by much more than this which, if maintained over a sustained period, would be expected to delay the need for surgery substantially.

Contributors

AHC, TC, MD, MF, and XYJ were investigators on the AIMS trial. GS was an investigator on the Canadian trial. MG and BM were investigators on the COMPARE trial. JDB was an investigator on the Ghent Marfan trial. AE, AF, and GT-T were investigators on the LOAT trial. CBo, GJ, and OM were investigators on the Marfan Sartan trial. HD, RVL, and LAS were investigators on the US National Institutes of Health (NIH) National Heart, Lung, and Blood Institute (NHLBI) Pediatric Heart Network (PHN) trial. H-HC and M-HW were investigators on the Taiwanese trial. AP, JE, CBa, SN, and HW conceived and designed the experiment. HH, KD, KW, LH, and ES did the systematic searches, data collection, and processing. KD, JE, and ES did the statistical analyses. CR provided clinical input and contributed to project oversight. AP and CBa drafted the first version of the manuscript. All authors critically revised the manuscript for important intellectual content. All authors accept full responsibility for the content of the paper and have seen and approved the final version.

Declaration of interests

AP has received grants paid to his institutions from the Marfan Foundation, the British Heart Foundation, the UK National Institute for Health and Care Research Biomedical Research Centre, the Gibson fund, Oxford University Hospitals Charitable Fund, and the Academy of Medical Sciences Clinical Lecturer Starter Grant scheme (which is administered by the Academy on behalf of the Academy, the Wellcome Trust, the UK Medical Research Council [MRC], the British Heart Foundation, Arthritis Research UK, Prostate Cancer UK, and the Royal College of Physicians). CR has received institutional grants from the British Heart Foundation and UK MRC. CBa has received institutional grants from the British Heart Foundation, UK MRC, NIHR, and Boehringer Ingelheim (EMPA-KIDNEY trial).

Data sharing

The NIH NHLBI PHN Marfan Study dataset was used in preparation of this work. Data were downloaded from <https://www.pediatricheartnetwork.org/login/> on Oct 15, 2019. Other individual participant datasets were provided to the Marfan Treatment Trialists' (MTT) secretariat in Oxford, UK, by the trialists. Data sharing requests for these trials should be sent to the principal investigators of the trials, who are: MF (m.flather@uea.ac.uk) for the AIMS trial; GS (gsandor@telus.net) for the Canadian Trial; MG (m.groenink@amc.uva.nl) for the COMPARE trial; JDB (Julie.DeBacker@UGent.be) for the Ghent Marfan trial; GT-T (gteixido@vhebron.net) for the LOAT trial; GJ (guillaume.jondeau@aphp.fr) for the Marfan-Sartan trial; RL (ron.lacro@cardio.chboston.org) for the PHN trial; and M-HW (wumh@ntu.edu.tw) for the Taiwanese trial.

Acknowledgments

The work of the MTT is supported by the Marfan Foundation, the Oxford British Heart Foundation Centre for Research Excellence, and the UK Medical Research Council (MC_UU_00017/4). AP acknowledges funding support from the Marfan Foundation, the British Heart Foundation, including from the Oxford British Heart Foundation Centre for Research Excellence (RE/13/1/30181), the UK National Institute for Health and Care Research Biomedical Research Centre, Oxford, the Gibson fund, Oxford University Hospitals Charitable Fund, and from an Academy of Medical Sciences Clinical Lecturer Starter Grant scheme, which is administered by the Academy on behalf of the Academy, the Wellcome Trust, the Medical Research Council, the British Heart Foundation, Arthritis Research UK, Prostate Cancer UK, and the Royal College of Physicians. We would like to thank all the participants who originally took part in the included trials, without whom this research would not have been possible. We would like to thank the clinicians, scientists, and all those who worked on the original trials. JDB would like to thank Laura Muiño Mosquera for her contributions to the Ghent Marfan trial. We would also like to thank Samantha Briggs and Clare Mathews for their valuable administrative assistance in preparing this report.

References

- 1 McKusick VA. The cardiovascular aspects of Marfan's syndrome: a heritable disorder of connective tissue. *Circulation* 1955; 11: 321–42.
- 2 Keane MG, Pyeritz RE. Medical management of Marfan syndrome. *Circulation* 2008; 117: 2802–13.

- 3 Dietz HC, Cutting GR, Pyeritz RE, et al. Marfan syndrome caused by a recurrent de novo missense mutation in the fibrillin gene. *Nature* 1991; **352**: 337–39.
- 4 Baetens M, Van Laer L, De Leener K, et al. Applying massive parallel sequencing to molecular diagnosis of Marfan and Loeys-Dietz syndromes. *Hum Mutat* 2011; **32**: 1053–62.
- 5 De Paepe A, Devereux RB, Dietz HC, Hennekam RC, Pyeritz RE. Revised diagnostic criteria for the Marfan syndrome. *Am J Med Genet* 1996; **62**: 417–26.
- 6 Loeys BL, Dietz HC, Braverman AC, et al. The revised Ghent nosology for the Marfan syndrome. *J Med Genet* 2010; **47**: 476–85.
- 7 Groth KA, Stochholm K, Hove H, Andersen NH, Gravholt CH. Causes of mortality in the Marfan syndrome (from a Nationwide Register Study). *Am J Cardiol* 2018; **122**: 1231–35.
- 8 Halpern BL, Char F, Murdoch JL, Horton WB, McKusick VA. A prospectus on the prevention of aortic rupture in the Marfan syndrome with data on survivorship without treatment. *Johns Hopkins Med J* 1971; **129**: 123–29.
- 9 Gersony DR, McCloughlin MA, Jin Z, Gersony WM. The effect of beta-blocker therapy on clinical outcome in patients with Marfan's syndrome: a meta-analysis. *Int J Cardiol* 2007; **114**: 303–08.
- 10 Shores J, Berger KR, Murphy EA, Pyeritz RE. Progression of aortic dilatation and the benefit of long-term beta-adrenergic blockade in Marfan's syndrome. *N Engl J Med* 1994; **330**: 1335–41.
- 11 Habashi JP, Judge DP, Holm TM, et al. Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome. *Science* 2006; **312**: 117–21.
- 12 Brooke BS, Habashi JP, Judge DP, Patel N, Loeys B, Dietz HC 3rd. Angiotensin II blockade and aortic-root dilation in Marfan's syndrome. *N Engl J Med* 2008; **358**: 2787–95.
- 13 Pees C, Laccone F, Hagl M, Debrauwer V, Moser E, Michel-Behnke I. Usefulness of losartan on the size of the ascending aorta in an unselected cohort of children, adolescents, and young adults with Marfan syndrome. *Am J Cardiol* 2013; **112**: 1477–83.
- 14 Mueller GC, Stierle L, Stark V, et al. Retrospective analysis of the effect of angiotensin II receptor blocker versus β -blocker on aortic root growth in paediatric patients with Marfan syndrome. *Heart* 2014; **100**: 214–18.
- 15 Muño-Mosquera L, De Nobele S, Devos D, Campens L, De Paepe A, De Backer J. Efficacy of losartan as add-on therapy to prevent aortic growth and ventricular dysfunction in patients with Marfan syndrome: a randomized, double-blind clinical trial. *Acta Cardiol* 2017; **72**: 616–24.
- 16 Bhatt AB, Buck JS, Zuflacht JP, et al. Distinct effects of losartan and atenolol on vascular stiffness in Marfan syndrome. *Vasc Med* 2015; **20**: 317–25.
- 17 Sandor GG, Alghamdi MH, Raffin LA, et al. A randomized, double blind pilot study to assess the effects of losartan vs atenolol on the biophysical properties of the aorta in patients with Marfan and Loeys-Dietz syndromes. *Int J Cardiol* 2015; **179**: 470–75.
- 18 Milleron O, Arnoult F, Ropers J, et al. Marfan Sartan: a randomized, double-blind, placebo-controlled trial. *Eur Heart J* 2015; **36**: 2160–66.
- 19 Gambarin FI, Favalli V, Serio A, et al. Rationale and design of a trial evaluating the effects of losartan vs nebivolol vs the association of both on the progression of aortic root dilation in Marfan syndrome with *FBN1* gene mutations. *J Cardiovasc Med (Hagerstown)* 2009; **10**: 354–62.
- 20 Groenink M, den Hartog AW, Franken R, et al. Losartan reduces aortic dilatation rate in adults with Marfan syndrome: a randomized controlled trial. *Eur Heart J* 2013; **34**: 3491–500.
- 21 Forteza A, Evangelista A, Sánchez V, et al. Efficacy of losartan vs atenolol for the prevention of aortic dilation in Marfan syndrome: a randomized clinical trial. *Eur Heart J* 2016; **37**: 978–85.
- 22 Chiu HH, Wu MH, Wang JK, et al. Losartan added to β -blockade therapy for aortic root dilation in Marfan syndrome: a randomized, open-label pilot study. *Mayo Clin Proc* 2013; **88**: 271–76.
- 23 Mullen M, Jin XY, Child A, et al. Irbesartan in Marfan syndrome (AIMS): a double-blind, placebo-controlled randomised trial. *Lancet* 2019; **394**: 2263–70.
- 24 Lacro RV, Dietz HC, Sleeper LA, et al. Atenolol versus losartan in children and young adults with Marfan's syndrome. *N Engl J Med* 2014; **371**: 2061–71.
- 25 Pitcher A, Emberson J, Lacro RV, et al. Design and rationale of a prospective, collaborative meta-analysis of all randomized controlled trials of angiotensin receptor antagonists in Marfan syndrome, based on individual patient data: a report from the Marfan Treatment Trialists' Collaboration. *Am Heart J* 2015; **169**: 605–12.
- 26 Elbadawi A, Omer MA, Elgendy IY, et al. Losartan for preventing aortic root dilatation in patients with Marfan syndrome: a meta-analysis of randomized trials. *Cardiol Ther* 2019; **8**: 365–72.
- 27 Al-Abcha A, Saleh Y, Mujer M, et al. Meta-analysis examining the usefulness of angiotensin receptor blockers for the prevention of aortic root dilation in patients with the Marfan syndrome. *Am J Cardiol* 2020; **128**: 101–06.
- 28 Kang YN, Chi SC, Wu MH, Chiu HH. The effects of losartan versus beta-blockers on cardiovascular protection in Marfan syndrome: a systematic review and meta-analysis. *J Formos Med Assoc* 2020; **119**: 182–90.
- 29 Campens L, Demulier L, De Groot K, et al. Reference values for echocardiographic assessment of the diameter of the aortic root and ascending aorta spanning all age categories. *Am J Cardiol* 2014; **114**: 914–20.
- 30 Pettersen MD, Du W, Skeens ME, Humes RA. Regression equations for calculation of Z scores of cardiac structures in a large cohort of healthy infants, children, and adolescents: an echocardiographic study. *J Am Soc Echocardiogr* 2008; **21**: 922–34.
- 31 Bhalal N, Emberson J, Merhi A, et al. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. *Lancet* 2013; **382**: 769–79.
- 32 Di Toro A, Klersy C, Giuliani L, et al. Losartan vs nebivolol vs the association of both on the progression of aortic root dilation in genotyped Marfan syndrome: 48 months open label randomized controlled phase III trial. *Eur Heart J* 2019; **40** (suppl 1): 3742.
- 33 Roman MJ, Devereux RB, Kramer-Fox R, O'Loughlin J. Two-dimensional echocardiographic aortic root dimensions in normal children and adults. *Am J Cardiol* 1989; **64**: 507–12.
- 34 Haycock GB, Schwarz GJ, Wisotsky DH. Geometric method for measuring body surface area: a height-weight formula validated in infants, children and adults. *J Pediatr* 1978; **93**: 62–66.
- 35 Du Bois D, Du Bois E F. A formula to estimate the approximate surface area if height and weight be known. *Arch Intern Med* 1916; **17**: 863–71.
- 36 Devereux RB, de Simone G, Arnett DK, et al. Normal limits in relation to age, body size and gender of two-dimensional echocardiographic aortic root dimensions in persons ≥ 15 years of age. *Am J Cardiol* 2012; **110**: 1189–94.
- 37 Sluysmans T, Colan SD. Theoretical and empirical derivation of cardiovascular allometric relationships in children. *J Appl Physiol* 2005; **99**: 445–57.
- 38 The Marfan Foundation. Marfan syndrome. <https://marfan.org/conditions/marfan-syndrome> (accessed 11 May, 2022).